Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence,” and the site revision label advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T20:35:21.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T20:49:23.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The LIBRETTO-431 page now shows a 403 Forbidden error, replacing the previous study details and removing associated documents, effectively blocking access to the trial's information.
    Difference
    19%
    Check dated 2026-09-22T22:18:54.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The page underwent a revision bump from v3.6.6 to v3.7.0, indicating a platform/template upgrade for the ClinicalTrials.gov page. This update does not modify the study details or displayed data.
    Difference
    0.0%
    Check dated 2026-09-15T20:46:31.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    Revision updated from v3.6.5 to v3.6.6, indicating a minor update to the record. This change does not modify the study text or data presented on the page.
    Difference
    0.0%
    Check dated 2026-09-01T18:24:54.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    A funding note '2019 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, indicating NIH support for the LIBRETTO-431 trial. This broadens the funding attribution in the study record.
    Difference
    0.0%
    Check dated 2026-08-25T19:40:59.000Z thumbnail image

Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.